HIV vaccine design and the neutralizing antibody problem

Dennis R. Burton(Scripps Research Institute), Ronald C. Desrosiers(New England Biolabs (United States)), Robert W. Doms(University of Pennsylvania), Wayne C. Koff(International AIDS Vaccine Initiative), Peter D. Kwong(National Institutes of Health), John P. Moore(Cornell University), Gary J. Nabel(National Institutes of Health), Joseph Sodroski(Dana-Farber Cancer Institute), Ian A. Wilson(Scripps Research Institute), Richard T. Wyatt(National Institutes of Health)

Nature Immunology

February 25, 2004

10.1038/ni0304-233

Cited by 765

Abstract

Related Papers

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Richard T. Wyatt, Joseph Sodroski|Science|1998|1.6k

Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

Erica Ollmann Saphire, Paul W.H.I. Parren, Ralph Pantophlet et al.|Science|2001|930

Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41

Michael B. Zwick, Aran F. Labrijn, Meng Wang et al.|Journal of Virology|2001|782

Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition

D.A. Calarese, Christopher N. Scanlan, Michael B. Zwick et al.|Science|2003|778

Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

Rogier W. Sanders, Mika Vesanen, Norbert Schuelke et al.|Journal of Virology|2002|454